FDA Approved: DEFERASIROX — Supplemental Application (Camber Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Deferasirox from Camber Pharmaceuticals, authorizing a generic product under ANDA 216229.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia
• Beta Thalassemia Major
• Myelodysplastic Syndromes
• Sickle Cell Disease

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

SUPPL AP for DEFERASIROX (DEFERASIROX)